In vitro stability and in vivo pharmacokinetic studies of a model opioid peptide, H-Tyr-D-Ala-Gly-Phe-D-Leu-OH (DADLE), and its cyclic prodrugs

Journal of Pharmacology and Experimental Therapeutics

Volumn 303, Issue 2, 2002, Pages 840-848

  Yang, Jerry Z ^a   Chen, Weiqing ^a   Borchardt, Ronald T ^a  

^a UNIVERSITY OF KANSAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENKEPHALIN[2 DEXTRO ALANINE 5 DEXTRO LEUCINE]; OPIATE PEPTIDE; PRODRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BIOTRANSFORMATION; BLOOD BRAIN BARRIER; CATALYSIS; DRUG BILE LEVEL; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG UPTAKE; DRUG URINE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIVER METABOLISM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BIOPHARMACEUTICS; BIOTRANSFORMATION; BLOOD PROTEINS; BRAIN; CYCLIZATION; DRUG STABILITY; ENKEPHALIN, LEUCINE-2-ALANINE; INJECTIONS, INTRAVENOUS; LIVER; MALE; NARCOTICS; PRODRUGS; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0036827812     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.037135     Document Type: Article

References (26)

1. Bak A, Gudmundsson OS, Friis GJ, Siahaan TJ, and Borchardt RT (1999a) Acyloxy-alkoxy-based cyclic prodrugs of opioid peptides: Evaluation of the chemical and enzymatic stability as well as their transport properties across Caco-2 cell monolayers. Pharm Res 16:24-29.
2. Bak A, Siahaan TJ, Gudmundsson OS, Gangwar S, Friis GJ, and Borchardt RT (1999b) Synthesis and evaluation of the physicochemical properties of esterase-sensitive cyclic prodrugs of opioid peptides using an (acyloxy)alkoxy linker. J Pept Res 53:393-402.
3. Chen W, Yang JZ, Andersen R, Nielsen LH, and Borchardt RT (2002) Evaluation of the permeation characteristics of a model opioid peptide, H-Tyr-D-Ala-Gly-Phe-D-Leu-OH (DADLE), and its cyclic prodrugs across the blood-brain barrier using an in situ perfused rat brain model. J Pharmacol Exp Ther 303:849-857.
4. Fricker G and Drewe J (1996) Current concepts in intestinal peptide absorption. J Pept Sci 2:195-211.
5. Greene DL, Hau VS, Abbruscato TJ, Bartosz H, Misicka A, Lipkowski AW, Hom S, Gillespie TJ, Hruby VJ, and Davis TP (1996) Enkephalin analog prodrugs: Assessment of in vitro conversion, enzyme cleavage characterization and blood-brain barrier permeability. J Pharmacol Exp Ther 277:1366-1375.
6. Gudmundsson OS, Jois SD, Vander Velde DG, Siahaan TJ, Wang B, and Borchardt RT (1999a) The effect of conformation on the membrane permeation of coumarinic acid- and phenylpropionic acid-based cyclic prodrugs of opioid peptides. J Pept Res 53:383-392.
7. Gudmundsson OS, Pauletti GM, Wang W, Shan D, Zhang H, Wang B, and Borchardt RT (1999b) Coumarinic acid-based cyclic prodrugs of opioid peptides that exhibit metabolic stability to peptidases and excellent cellular permeability. Pharm Res 16:7-15.
8. Gudmundsson OS, Vander Velde DG, Jois SD, Bak A, Siahaan TJ, and Borchardt RT (1999c) The effect of conformation of the acyloxyalkoxy-based cyclic prodrugs of opioid peptides on their membrane permeability. J Pept Res 53:403-413.
9. Huang TL, Shiotsuki T, Uematsu T, Borhan B, Li QX, and Hammock BD (1996) Structure-activity relationships for substrates and inhibitors of mammalian liver microsomal carboxylesterases. Pharm Res 13:1495-1500.
10. Misicka A, Maszczynska I, Lipkowski AW, Stropova D, Yamamura HI, and Hruby VJ (1996) Synthesis and biological properties of γ-glutamyl-dermorphin, a prodrug. Life Sci 58:905-911.
11. Ouyang H, Tang F, Siahaan TJ, and Borchardt RT (2002a) A modified coumarinic acid-based cyclic prodrug of an opioid peptide: Enzymatic and chemical stability and membrane permeation characteristics. Pharm Res 19:794-801.
12. Ouyang H, Borchardt RT, Siahaan TJ, and Vander Velde DG (2002b) Synthesis and conformational analysis of a coumarinic acid-based cyclic prodrug of an opioid peptide with modified sensitivity to esterase-catalyzed bioconversion. J Pept Res 59:183-195.
13. Patel D, McKinley BD, Davis TP, Porreca F, Yamamura HI, and Hruby VJ (1997) Peptide targeting and delivery across the blood-brain barrier utilizing synthetic triglyceride esters: Design, synthesis and bioactivity. Bioconjug Chem 8:434-441.
14. Pauletti GM, Gangwar S, Knipp GT, Nerurkar MM, Okumu FW, Tamura K, Siahaan TJ, and Borchardt RT (1996a) Structural requirements for intestinal absorption of peptide drugs. J Control Release 41:3-17.
15. Pauletti GM, Gangwar S, Okumu FW, Siahaan TJ, Stella VJ, and Borchardt RT (1996b) Esterase-sensitive cyclic prodrugs of peptides: Evaluation of an acyloxy-alkoxy promoiety in a model hexapeptide. Pharm Res 13:1615-1623.
16. Pauletti GM, Gangwar S, Siahaan TJ, Aube J, and Borchardt RT (1997) Improvement of oral peptide bioavailability: Peptidomimetics and prodrug strategies. Adv Drug Deliv Rev 27:235-256.
17. Prokai L (1998) Peptide drug delivery into the central nervous system. Prog Drug Res 51:95-131.
18. Prokai L, Prokai-Tatrai K, and Bodor N (2000) Targeting drugs to the brain by redox chemical delivery systems. Med Res Rev 20:367-416.
19. Raub TJ, Barsuhn CL, Williams LR, Decker DE, Sawada GA, and Ho NF (1993) Use of a biophysical-kinetic model to understand the roles of protein binding and membrane partitioning on passive diffusion of highly lipophilic molecules across cellular barriers. J Drug Target 1:269-286.
20. Sawyer TK (1995) Peptidomimetic design and chemistry approaches to peptide metabolism, in Peptide-Based Drug Design: Controlling Transport and Metabolism (Taylor MD and Amidon GL eds) pp 387-422, American Chemical Society, Washington DC.
21. Takahashi K, Tamagawa S, Sakano H, Katagi T, and Mizuno N (1995) Effects of the ester moiety on stereoselective hydrolysis of several propranolol prodrugs in rat tissues. Biol Pharm Bull 18:1401-1404.
22. Tang F and Borchardt RT (2002a) Characterization of the efflux transporter(s) responsible for restricting intestinal mucosa permeation of an acyloxyalkoxy-based cyclic prodrug of the opioid peptide DADLE. Pharm Res 19:780-786.
23. Tang F and Borchardt RT (2002b) Characterization of the efflux transporter(s) responsible for restricting intestinal mucosa permeation of the coumarinic acid-based cyclic prodrug of the opioid peptide DADLE. Pharm Res 19:787-793.
24. Walker CH and Mackness MI (1987) "A" esterases and their role in regulating the toxicity of organophosphates. Arch Toxicol 60:30-33.
25. Wang B, Nimkar K, Wang W, Zhang H, Shan D, Gudmundsson O, Gangwar S, Siahaan T, and Borchardt RT (1999) Synthesis and evaluation of the physicochemical properties of esterase-sensitive cyclic prodrugs of opioid peptides using coumarinic acid and phenylpropionic acid linkers. J Pept Res 53:370-382.
26. Yang JZ, Bastian KC, Moore RD, Stobaugh JF, and Borchardt RT (2002) Quantitative analysis of a model opioid peptide and its cyclic prodrugs in rat plasma using high-performance liquid chromatography with fluorescence and tandem mass spectrometric detection. J Chromatogr B, in press.